Literature DB >> 34070643

Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine.

Marco Casadio1, Francesca Biancaniello1, Diletta Overi2, Rosanna Venere1, Guido Carpino3, Eugenio Gaudio2, Domenico Alvaro1, Vincenzo Cardinale4.   

Abstract

Cholangiocarcinomas (CCAs) are heterogeneous biliary tract malignancies with dismal prognosis, mainly due to tumor aggressiveness, late diagnosis, and poor response to current therapeutic options. High-throughput technologies have been used as a fundamental tool in unveiling CCA molecular landscape, and several molecular classifications have been proposed, leading to various targeted therapy trials. In this review, we aim to analyze the critical issues concerning the status of precision medicine in CCA, discussing molecular signatures and clusters, related to both anatomical classification and different etiopathogenesis, and the latest therapeutic strategies. Furthermore, we propose an integrated approach comprising the CCA molecular mechanism, pathobiology, clinical and histological findings, and treatment perspectives for the ultimate purpose of improving the methods of patient allocations in clinical trials and the response to personalized therapies.

Entities:  

Keywords:  cholangiocarcinoma; molecular signatures; precision medicine; targeted therapy

Year:  2021        PMID: 34070643     DOI: 10.3390/ijms22115613

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  57 in total

1.  Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities.

Authors:  Benjamin Goeppert; Trine Folseraas; Stephanie Roessler; Peter Schirmacher; Tom H Karlsen; Matthias Kloor; Anna-Lena Volckmar; Volker Endris; Ivo Buchhalter; Albrecht Stenzinger; Krzysztof Grzyb; Marit M Grimsrud; Barbara Gornicka; Erik von Seth; Gary M Reynolds; Andre Franke; Daniel N Gotthardt; Arianeb Mehrabi; Angela Cheung; Joanne Verheij; Johanna Arola; Heikki Mäkisalo; Tor J Eide; Sören Weidemann; John C Cheville; Giuseppe Mazza; Gideon M Hirschfield; Cyriel Y Ponsioen; Annika Bergquist; Piotr Milkiewicz; Konstantinos N Lazaridis; Christoph Schramm; Michael P Manns; Martti Färkkilä; Arndt Vogel; Kirsten M Boberg
Journal:  Hepatology       Date:  2020-08-19       Impact factor: 17.425

2.  A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.

Authors:  Renuka V Iyer; Venkata K Pokuri; Adrienne Groman; Wen W Ma; Usha Malhotra; Dan M Iancu; Catherine Grande; Tanios B Saab
Journal:  Am J Clin Oncol       Date:  2018-07       Impact factor: 2.339

3.  Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

Authors:  Daniela Sia; Yujin Hoshida; Augusto Villanueva; Sasan Roayaie; Joana Ferrer; Barbara Tabak; Judit Peix; Manel Sole; Victoria Tovar; Clara Alsinet; Helena Cornella; Brandy Klotzle; Jian-Bing Fan; Christian Cotsoglou; Swan N Thung; Josep Fuster; Samuel Waxman; Juan Carlos Garcia-Valdecasas; Jordi Bruix; Myron E Schwartz; Rameen Beroukhim; Vincenzo Mazzaferro; Josep M Llovet
Journal:  Gastroenterology       Date:  2013-01-04       Impact factor: 22.682

Review 4.  Biliary tract cancer.

Authors:  Juan W Valle; R Katie Kelley; Bruno Nervi; Do-Youn Oh; Andrew X Zhu
Journal:  Lancet       Date:  2021-01-30       Impact factor: 79.321

5.  Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

Authors:  Jeeyun Lee; Se Hoon Park; Heung-Moon Chang; Jun Suk Kim; Hye Jin Choi; Myung Ah Lee; Joung Soon Jang; Joung Soon Chang; Hei Cheul Jeung; Jung Hun Kang; Hyun Woo Lee; Dong Bok Shin; Hye Jin Kang; Jong-Mu Sun; Joon Oh Park; Young Suk Park; Won Ki Kang; Ho Yeong Lim
Journal:  Lancet Oncol       Date:  2011-12-20       Impact factor: 41.316

6.  Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

Authors:  Ghassan K Abou-Alfa; Vaibhav Sahai; Antoine Hollebecque; Gina Vaccaro; Davide Melisi; Raed Al-Rajabi; Andrew S Paulson; Mitesh J Borad; David Gallinson; Adrian G Murphy; Do-Youn Oh; Efrat Dotan; Daniel V Catenacci; Eric Van Cutsem; Tao Ji; Christine F Lihou; Huiling Zhen; Luis Féliz; Arndt Vogel
Journal:  Lancet Oncol       Date:  2020-03-20       Impact factor: 41.316

7.  Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study.

Authors:  R Buzzoni; S Pusceddu; E Bajetta; F De Braud; M Platania; C Iannacone; M Cantore; A Mambrini; A Bertolini; O Alabiso; A Ciarlo; C Turco; V Mazzaferro
Journal:  Ann Oncol       Date:  2014-05-14       Impact factor: 32.976

8.  Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.

Authors:  David K Lau; Rebecca Y Tay; Yvonne H Yeung; Fiona Chionh; Jennifer Mooi; Carmel Murone; Effie Skrinos; Timothy J Price; John M Mariadason; Niall C Tebbutt
Journal:  Br J Cancer       Date:  2018-03-12       Impact factor: 7.640

9.  Applied precision cancer medicine in metastatic biliary tract cancer.

Authors:  H Taghizadeh; L Müllauer; R Mader; G W Prager
Journal:  Hepatol Int       Date:  2020-02-25       Impact factor: 6.047

Review 10.  Molecular Targets in Cholangiocarcinoma.

Authors:  Colm J O'Rourke; Patricia Munoz-Garrido; Jesper B Andersen
Journal:  Hepatology       Date:  2020-12-03       Impact factor: 17.425

View more
  3 in total

Review 1.  Precision Medicine in Cholangiocarcinoma: Past, Present, and Future.

Authors:  Chi-Yuan Cheng; Chiao-Ping Chen; Chiao-En Wu
Journal:  Life (Basel)       Date:  2022-06-02

Review 2.  A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?

Authors:  Giacomo Aimar; Chiara Paratore; Clizia Zichi; Donatella Marino; Elisa Sperti; Andrea Caglio; Teresa Gamba; Francesca De Vita; Massimo Di Maio
Journal:  Explor Target Antitumor Ther       Date:  2021-10-31

3.  Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis.

Authors:  Kwangrok Jung; Jaewoo Park; Jae Hyup Jung; Jong-Chan Lee; Jaihwan Kim; Jin-Hyeok Hwang
Journal:  Gut Liver       Date:  2022-01-07       Impact factor: 4.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.